Item |
NCM/SH |
Medicamentos e Reagentes Químicos |
1 |
3002.10.39 |
CERA 1000 mcg |
2 |
3002.10.39 |
CERA 400 mcg |
3 |
3002.10.39 |
CERA 200 mcg |
4 |
3002.10.39 |
CERA 100 mcg |
5 |
3002.10.39 |
CERA 50 mcg |
12 |
3002.10.38 |
Bevacizumab 100 mg |
15 |
3004.90.59 |
Docetaxel 20 mg |
16 |
3004.90.59 |
Docetaxel 80 mg |
21 |
3004.90.99 |
Cisplatina 50 mg |
22 |
3002.10.38 |
Rituximab 100 mg |
23 |
3002.10.38 |
Rituximab 500 mg |
30 |
3002.10.39 |
Tocilizumab 200 mg |
"
Cláusula segunda - Ficam acrescidos os itens 44 a 68 ao Anexo Único do Convênio ICMS 9/07, com as seguintes redações:
"
Item |
NCM/SH |
Medicamentos e Reagentes Químicos |
44 |
3004.31.00 |
Insulina Glargina 100 unidades/ml |
45 |
3004.90.99 |
RO4998452 – 2,5 mg |
46 |
3004.90.99 |
RO4998452 – 10 mg |
47 |
3004.90.99 |
RO4998452 – 20 mg |
48 |
3004.90.99 |
RO4998452 ou placebo |
49 |
3004.90.99 |
RO4998452 inibidor SGLT2 |
50 |
3004.90.39 |
Taspoglutida – 10 mg |
51 |
3004.90.39 |
Taspoglutida – 20 mg |
52 |
3004.90.39 |
Taspoglutida ou placebo |
53 |
3004.90.79 |
Aleglitazar |
54 |
3004.90.79 |
RO5072759 – 50 mg |
55 |
3004.90.79 |
Pioglitazona – 45 mg |
56 |
3004.90.79 |
Pioglitazona – 30 mg |
57 |
3004.90.79 |
Pioglitazona ou placebo |
58 |
3004.90.99 |
Erlotinib ou placebo |
59 |
3004.90.99 |
Erlotinib 150 mg |
60 |
3002.10.38 |
Trastuzumab MCC DMI 160 mg liofilisado |
61 |
3004.90.79 |
Lapatinib 250 mg |
62 |
3002.10.38 |
Trastuzumab 120 mg + rHuPH20 2000 unidades |
63 |
3002.10.38 |
Rituximab 1200 mg + rHuPH20 2000 unidades |
64 |
3004.90.69 |
Fluorouracil |
65 |
3002.10.39 |
Tocilizumab |
66 |
3002.10.39 |
Pertuzumab |
67 |
3002.10.39 |
Ocrelizumab |
68 |
3004.90.99 |
DPP – IV inhibitor |